Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review
Chelsea S. Pan, Takara L. Stanley
Frontiers in Endocrinology (2020) Vol. 11
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review
Bertrand Cariou, Christopher D. Byrne, Rohit Loomba, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 5, pp. 1069-1083
Open Access | Times Cited: 143
Metabolic liver disease in diabetes – From mechanisms to clinical trials
Bedair Dewidar, S. Kahl, Kalliopi Pafili, et al.
Metabolism (2020) Vol. 111, pp. 154299-154299
Open Access | Times Cited: 133
Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021–025
Elke Roeb, Ali Canbay, Frank Tacke, et al.
Zeitschrift für Gastroenterologie (2022) Vol. 60, Iss. 09, pp. 1346-1421
Open Access | Times Cited: 53
European guideline on obesity care in patients with gastrointestinal and liver diseases – Joint ESPEN/UEG guideline
Stephan C. Bischoff, Rocco Barazzoni, Luca Busetto, et al.
Clinical Nutrition (2022) Vol. 41, Iss. 10, pp. 2364-2405
Open Access | Times Cited: 38
European guideline on obesity care in patients with gastrointestinal and liver diseases – Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline
Stephan C. Bischoff, Rocco Barazzoni, Luca Busetto, et al.
United European Gastroenterology Journal (2022) Vol. 10, Iss. 7, pp. 663-720
Open Access | Times Cited: 38
Management of metabolic-associated fatty liver disease: The diabetology perspective
Mohammad Sadiq Jeeyavudeen, Shahanas K A Khan, Sherouk Fouda, et al.
World Journal of Gastroenterology (2023) Vol. 29, Iss. 1, pp. 126-143
Open Access | Times Cited: 33
A multistakeholder approach to innovations in NAFLD care
Jörn M. Schattenberg, Alina M. Allen, Helen Jarvis, et al.
Communications Medicine (2023) Vol. 3, Iss. 1
Open Access | Times Cited: 22
The impact of metformin on weight and metabolic parameters in patients with obesity: A systematic review and meta‐analysis of randomized controlled trials
Rachelle Haber, Fatima Zarzour, Malak Ghezzawi, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 5, pp. 1850-1867
Closed Access | Times Cited: 8
A High-Fat Diet Attenuates AMPK α1 in Adipocytes to Induce Exosome Shedding and Nonalcoholic Fatty Liver Development In Vivo
Chenghui Yan, Xiaoxiang Tian, Jiayin Li, et al.
Diabetes (2020) Vol. 70, Iss. 2, pp. 577-588
Open Access | Times Cited: 69
Semaglutide Modulates Extracellular Matrix Production of LX-2 Cells via Exosomes and Improves Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Maria Principia Scavo, Giuseppe Lisco, Nicoletta Depalo, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1493-1493
Open Access | Times Cited: 7
Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Amani Elshaer, David M. Chascsa, Blanca Lizaola‐Mayo
Life (2024) Vol. 14, Iss. 7, pp. 844-844
Open Access | Times Cited: 6
Weight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomes
Nick Finer
Diabetes Obesity and Metabolism (2021) Vol. 24, Iss. S2, pp. 44-54
Open Access | Times Cited: 36
Non-Alcoholic Fatty Liver Disease (NAFLD) and Bariatric/Metabolic Surgery as Its Treatment Option: A Review
Paulina Głuszyńska, Dorota Lemancewicz, J Dzięcioł, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 24, pp. 5721-5721
Open Access | Times Cited: 36
Treatment of obesity and metabolic-associated fatty liver disease with a diet or orlistat: A randomized controlled trial
Xiongcai Feng, Yansong Lin, Shuyu Zhuo, et al.
American Journal of Clinical Nutrition (2023) Vol. 117, Iss. 4, pp. 691-700
Open Access | Times Cited: 13
Resmetirom and Metabolic Dysfunction-Associated Steatohepatitis: Perspectives on Multidisciplinary Management from Global Healthcare Professionals
K.F. Au, Ming‐Hua Zheng, Wei‐Jei Lee, et al.
Current Obesity Reports (2024) Vol. 13, Iss. 4, pp. 818-830
Closed Access | Times Cited: 5
SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews
Shih‐Chieh Shao, Liang‐Tseng Kuo, Rong‐Nan Chien, et al.
BMJ Open Diabetes Research & Care (2020) Vol. 8, Iss. 2, pp. e001956-e001956
Open Access | Times Cited: 36
Updated S2k Clinical Practice Guideline on Non-alcoholic Fatty Liver Disease (NAFLD) issued by the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) – April 2022 – AWMF Registration No.: 021–025

Zeitschrift für Gastroenterologie (2022) Vol. 60, Iss. 09, pp. e733-e801
Open Access | Times Cited: 21
Therapeutic Potentials of Reducing Liver Fat in Non-Alcoholic Fatty Liver Disease: Close Association with Type 2 Diabetes
Georgios Tsamos, Dimitra Vasdeki, Theocharis Koufakis, et al.
Metabolites (2023) Vol. 13, Iss. 4, pp. 517-517
Open Access | Times Cited: 12
Current and emerging medications for the management of obesity in adults
Rosalind Walmsley, Priya Sumithran
The Medical Journal of Australia (2023) Vol. 218, Iss. 6, pp. 276-283
Open Access | Times Cited: 11
Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis
Huan Xue, Hao-Jie Xing, B. Wang, et al.
Drug Design Development and Therapy (2023) Vol. Volume 17, pp. 1417-1432
Open Access | Times Cited: 10
Weight loss breaks the bond between nonalcoholic fatty liver disease and cardiovascular diseases: A clinical and epidemiological perspective
Moein Ala, Seyed Parsa Eftekhar
Obesity Reviews (2023) Vol. 24, Iss. 6
Closed Access | Times Cited: 6
Oral Ionic Liquid for Transdermal Delivery and Obesity Treatment
Beibei Lü, Chengyu Wu, Jichuan Zhang, et al.
ACS Biomaterials Science & Engineering (2023) Vol. 9, Iss. 6, pp. 3356-3367
Closed Access | Times Cited: 5
Efficacy of Weight Reduction on Pediatric Nonalcoholic Fatty Liver Disease: Opportunities to Improve Treatment Outcomes Through Pharmacotherapy
Chance S. Friesen, Chelsea M. Hosey, Sherwin S. Chan, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 12
Utilization and perspectives of weight loss medications in pediatric metabolic dysfunction‐associated steatotic liver disease
Mohit Kehar, Samar H. Ibrahim, Charina M. Ramirez, et al.
Journal of Pediatric Gastroenterology and Nutrition (2024) Vol. 79, Iss. 3, pp. 661-666
Closed Access | Times Cited: 1
Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice
Bin Wang, Xiaochan Zhu, Siting Yu, et al.
Biochemical and Biophysical Research Communications (2024) Vol. 722, pp. 150170-150170
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top